These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 19949917)

  • 1. Multidrug resistance in cancer.
    Baguley BC
    Methods Mol Biol; 2010; 596():1-14. PubMed ID: 19949917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrins and extracellular matrix: a novel mechanism of multidrug resistance.
    Elliott T; Sethi T
    Expert Rev Anticancer Ther; 2002 Aug; 2(4):449-59. PubMed ID: 12647988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of selected anti-tumour therapeutic agents and reasons for multidrug resistance occurrence.
    Sawicka M; Kalinowska M; Skierski J; Lewandowski W
    J Pharm Pharmacol; 2004 Sep; 56(9):1067-81. PubMed ID: 15324475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms and functional aspects of multidrug resistance in Ehrlich ascites tumour cells.
    Nielsen DL
    Dan Med Bull; 2004 Nov; 51(4):393-414. PubMed ID: 16009064
    [No Abstract]   [Full Text] [Related]  

  • 5. [Resistance of hematologic neoplasm cells to cytostatics. Part II].
    Kodydková K; Krejsek J
    Cas Lek Cesk; 2000 Sep; 139(19):591-5. PubMed ID: 11192750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolutionary malignant resistance of cells to damaging factors as common biological defence mechanism in neoplastic development. Review of conception.
    Monceviciute-Eringiene E
    J Exp Clin Cancer Res; 2000 Sep; 19(3):335-48. PubMed ID: 11144527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming drug-resistant cancer by a newly developed copper chelate through host-protective cytokine-mediated apoptosis.
    Mookerjee A; Mookerjee Basu J; Dutta P; Majumder S; Bhattacharyya S; Biswas J; Pal S; Mukherjee P; Raha S; Baral RN; Das T; Efferth T; Sa G; Roy S; Choudhuri SK
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4339-49. PubMed ID: 16857809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors.
    Coley HM
    Methods Mol Biol; 2010; 596():341-58. PubMed ID: 19949931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention.
    Kaye SB
    Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S15-9. PubMed ID: 9801854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy.
    Walker J; Martin C; Callaghan R
    Eur J Cancer; 2004 Mar; 40(4):594-605. PubMed ID: 14962729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential.
    Alemán C; Annereau JP; Liang XJ; Cardarelli CO; Taylor B; Yin JJ; Aszalos A; Gottesman MM
    Cancer Res; 2003 Jun; 63(12):3084-91. PubMed ID: 12810633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence cancer stem cells--made by cell fusion?
    Dittmar T; Nagler C; Schwitalla S; Reith G; Niggemann B; Zänker KS
    Med Hypotheses; 2009 Oct; 73(4):542-7. PubMed ID: 19564079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
    Matsumoto Y; Takano H; Nagao S; Fojo T
    Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the cancer stem cell population "a player" in multi-drug resistance?
    Drewa T; Styczynski J; Szczepanek J
    Acta Pol Pharm; 2008; 65(4):493-500. PubMed ID: 19051593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The great multidrug-resistance paradox.
    Chen VY; Rosania GR
    ACS Chem Biol; 2006 Jun; 1(5):271-3. PubMed ID: 17163753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumvention.
    Harasym TO; Liboiron BD; Mayer LD
    Methods Mol Biol; 2010; 596():291-323. PubMed ID: 19949929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemosensitization of solid tumors by modulation of resistance mechanisms.
    Cree IA; Knight L; Di Nicolantonio F; Sharma S; Gulliford T
    Curr Opin Investig Drugs; 2002 Apr; 3(4):634-40. PubMed ID: 12090736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (+/-)-3'-O, 4'-O-dicynnamoyl-cis-khellactone, a derivative of (+/-)-praeruptorin A, reverses P-glycoprotein mediated multidrug resistance in cancer cells.
    Shen X; Chen G; Zhu G; Fong WF
    Bioorg Med Chem; 2006 Nov; 14(21):7138-45. PubMed ID: 16875827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do stem-like cells play a role in drug resistance of sarcomas?
    Honoki K
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):261-70. PubMed ID: 20132001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of multidrug resistance in cancer.
    Gillet JP; Gottesman MM
    Methods Mol Biol; 2010; 596():47-76. PubMed ID: 19949920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.